Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Procter & Gamble HealthBOM:500126 -0.81%86 Days Payable is 188.82 as of Mar. 2026, which is 66% above its 10-year median of 113.58. GuruFocus rates BOM:500126 with a GF Score™ of 86/100 and a GF Value™ of ₹6,061.14 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 925 Drug Manufacturers companies, Procter & Gamble Health ranks better than 82.16% on this metric.
The historical rank and industry rank for Procter & Gamble Health's Days Payable or its related term are showing as below:
BOM:500126'
s Days Payable Range Over the Past 10 Years
Min: 35.16 Med: 113.58 Max: 205.12
Current: 183.71
During the past 13 years, Procter & Gamble Health's highest Days Payable was 205.12. The lowest was 35.16. And the median was 113.58.
BOM:500126's Days Payable is ranked better than 82.16% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:500126: 183.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Procter & Gamble Health's Days Payable for the fiscal year that ended in Jun. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procter & Gamble Health (BOM:500126) has a Days Payable of 188.82 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Procter & Gamble Health and its competitors. This is 66% above median its historical median of 113.58. Over the past decade, Procter & Gamble Health's Days Payable has ranged from 35.16 to 205.12. According to the industry distribution chart, Procter & Gamble Health ranks #165 out of 925 companies in the Drug Manufacturers industry, placing it in the top 17.8%.
Is Procter & Gamble Health's Days Payable too high?
Procter & Gamble Health's current Days Payable of 188.82 is 66% above median its 10-year median of 113.58. Over the past 10 years, this metric has ranged from a low of 35.16 to a high of 205.12. The Drug Manufacturers industry median Days Payable is 90.38. Procter & Gamble Health's value of 188.82 is 108.9% above this industry median. Based on the distribution chart, Procter & Gamble Health ranks #165 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Procter & Gamble Health has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #165 out of 925 companies for Days Payable. This places Procter & Gamble Health in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Procter & Gamble Health's value of 188.82 is 108.9% above this benchmark. Historically, Procter & Gamble Health's own Days Payable has ranged from 35.16 to 205.12 over the past decade. While the company's 10-year median is 113.58 vs. the industry median of 90.38, Procter & Gamble Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current Days Payable of 188.82 is 108.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current Days Payable is 188.82, which is 66% above median its own 10-year median of 113.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6,061.14, compared to a current price of ₹6,792.75 — trading 12.1% above its estimated fair value. The current Days Payable is 188.82, which is 66% above median its 10-year median of 113.58 and 108.9% above the Drug Manufacturers industry median of 90.38. Procter & Gamble Health's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current Days Payable is 188.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be overvalued.
The current stock price of ₹6,792.75 is trading 12.1% above its estimated GF Value™ of ₹6,061.14.
GuruFocus considers Procter & Gamble Health to be Modestly Overvalued.
Key valuation signals for BOM:500126:
Days Payable: 188.82 (66% above median its 10-year median of 113.58)
GF Value™: ₹6,061.14 vs. price of ₹6,792.75 (12.1% above fair value)
Industry Position: 108.9% above the Drug Manufacturers median (#165 of 925)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
86GF Score
Get the complete analysis for BOM:500126
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
